Psoriasis

Patients with a later onset of psoriasis (PsO) may benefit from earlier screening for psoriatic arthritis (PsA), according to one study.

A bidirectional risk between psoriasis and asthma has been identified, according to one study.

Researchers have identified a link between psoriasis and the autoimmune diseases hypothyroidism and alopecia areata.

Chesahna Kindred, MD, MBA, FAAD, board-certified dermatologist, Kindred Hair & Skin Center, discusses how diversity in clinical trials are helping bridge the racial health equity gap in psoriasis care.

Researchers evaluated the impact of different treatment modalities in the prevention of psoriatic arthritis (PsA).

Patients with moderate to severe psoriasis may benefit from weekend cyclosporine treatment (WCT) as a maintenance therapy, according to one study.

Psychological well-being should be considered in the management of psoriasis, research indicates.

Chesahna Kindred, MD, MBA, FAAD, board-certified dermatologist, Kindred Hair & Skin Center, discusses ways to overcome barriers in clinical trials for diverse patients with psoriasis.

Botulinum toxin A (BoNT-A) exhibited promising results for nail psoriasis for up to 6 months with a single injection.

Chesahna Kindred, MD, MBA, FAAD, board-certified dermatologist, Kindred Hair & Skin Center, discusses how to accurately represent findings from diverse populations and translate them into clinical practice.

Efficacy results support long-term use of risankizumab in patients with active psoriatic arthritis across multiple patient and psoriatic disease characteristics.

Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.

Joseph Zabinski, PhD, MEM, vice president, head of commercial strategy and AI, OM1, addresses challenges in identifying patients with generalized pustular psoriasis (GPP) and how artificial intelligence (AI) can help alleviate these concerns.

Patients with moderate to severe psoriasis and a history of cancer have improved symptoms and a favorable safety profile with guselkumab treatment, according to a new study.

Joseph Zabinski, PhD, MEM, vice president, head of commercial strategy and AI, OM1, discusses ways that AI is being integrated into personalized medicine for patients with generalized pustular psoriasis (GPP).

Roflumilast cream may be suitable for chronic treatment, including the face and intertriginous areas, according to one study.

Posters presented at the American Academy of Dermatology Annual Meeting identified significant undertreatment of psoriasis and significant gaps in biologic medication treatment.

Laura Ferris, MD, PhD, professor of dermatology, University of Pittsburgh, reports promising response rates and a good safety profile with JNJ-2113 in patients with moderate to severe plaque psoriasis.

Posters presented at the American Academy of Dermatology Annual Meeting demonstrated both short- and long-term efficacy and safety profiles of brodalumab in patients with moderate to severe psoriasis.

Patients experienced clinically meaningful improvements in health-related quality of life (HRQoL) factors after 6 months of guselkumab, according to one study.

Study findings show that scores on the Psoriasis Area and Severity Index and the Dermatology Quality of Life Index are correlated in patients with psoriasis across several continents, but factors affecting each of these scores are different across countries.

Researchers suggest an alternative method to align drug prices with clinical benefits for patients with psoriasis.

It is important to study the safety of targeted therapies in populations at increased risk of skin cancer, according to the researchers.

Risankizumab is an effective treatment option for patients with psoriatic arthritis (PsA), according to a recent meta-analysis.

Continuous improvement was observed across the different domains of minimal disease activity criteria with guselkumab.